Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis

References

• WHO Coronavirus (COVID-19) Dashboard [Internet]. 2022 June 23. [cited 2022 Jul 26]. Available from: https://covid19.who.int.
   Google Scholar
• Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. New Engl J Med. 2021;385:1078–1090.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021;385:2348–2360.
   PubMed Web of Science ®Google Scholar
• Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): update from the advisory committee on immunization practices — United States, July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1094–1099.
   PubMed Web of Science ®Google Scholar
• Israeli Ministry of Health. 2022. Surveillance of myocarditis (Inflammation of the Heart Muscle) Cases Between December 2020 and May 2021 (Including) [Internet]. GOV.IL. [cited 2022 Mar 19]. Available from: https://www.gov.il/en/departments/news/01062021-03.
   Google Scholar
• Montgomery J, Ryan M, Engler R, et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. 2021;6(10):1202–1206.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Patone M, Mei XW, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021;374:1931.
   PubMed Web of Science ®Google Scholar
• Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225–228.
   PubMed Web of Science ®Google Scholar
• Najafzadeh M, Gagne JJ, Schneeweiss S. Synergies from integrating randomized controlled trials and real-world data analyses. Clin Pharmacol Ther. 2017;102(6):914–916.
   PubMed Web of Science ®Google Scholar
• Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 Million residents. JAMA Cardiol. 2022;7(6):600–612 .
   PubMed Web of Science ®Google Scholar
• Whiteley WN, Ip S, Cooper JA, et al. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: a population-based cohort study of 46 million adults in England. PLoS Med. 2022;19(2):e1003926.
   PubMed Web of Science ®Google Scholar
• Ip S, Torabi F, Denaxas S, et al. Risk of myocarditis and pericarditis following BNT162b2 and ChAdOx1 COVID-19 vaccinations. medRxiv [Internet]. 2022; Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L2017610856&from=export
   Google Scholar
• Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.
   PubMed Web of Science ®Google Scholar
• Munn Z, Moola S, Riitano D, et al. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag. 2014;3:123–128.
   PubMedGoogle Scholar
• Munn Z, Moola S, Lisy K, et al. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13:147–153.
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O’Connell D, et al. The Newcastle–Ottawa scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. 2014 [cited 2022 Jul 10]. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Tome J, Cowan LT, Fung IC-H. A pharmacoepidemiological study of myocarditis and pericarditis following mRNA COVID-19 vaccination in Europe. medRxiv. 2022 May 27 [cited 2022 Jul 26]:22275706. Internet Available from: https://www.medrxiv.org/content/10.1101/2022.05.27.22275706v2
   Google Scholar
• Simone A, Herald J, Chen A, et al. Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older. JAMA Intern Med. 2021;181(12):1668–1670.
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Balicer RD. Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 infection, according to age and sex. N Engl J Med. 2021;385(24):2299.
   PubMed Web of Science ®Google Scholar
• Lee CW, Sa S, Hong M, et al. Adverse events and safety profile of the COVID-19 vaccines in adolescents: safety monitoring for adverse events using real-world data. Vaccines (Basel). 2022;10(5):744.
   PubMed Web of Science ®Google Scholar
• Lai FTT, Chua GT, Chan EWW, et al. Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study. Emerg Microbes Infect. 2022;11(1):885–893.
   PubMed Web of Science ®Google Scholar
• Cari L, Alhosseini MN, Fiore P, et al. Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data. J Autoimmun. 2021;125:102742.
   PubMed Web of Science ®Google Scholar
• Lai FTT, Li X, Peng K, et al. Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine : a case-control study. Ann Intern Med. 2022;175:362–370.
   PubMed Web of Science ®Google Scholar
• Dickerman BA, Madenci AL, Gerlovin H, et al. Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans. JAMA Intern Med. 2022;182(7):739–746.
   PubMed Web of Science ®Google Scholar
• Chou OHI, Zhou J, Lee TTL, et al. Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study. Clin Res Cardiol. 2022;111(10):1098–1103.
   PubMedGoogle Scholar
• Hause AM, Gee J, Baggs J, et al. COVID-19 vaccine safety in adolescents aged 12-17 years - United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1053–1058.
   PubMed Web of Science ®Google Scholar
• Wong H-L, Hu M, Zhou CK, et al. elevated risk of myocarditis/pericarditis following COVID-19 mRNA vaccination in the United States [Internet]. Rochester, NY: Social Science Research Network; 2022 [cited 2022 Mar 21]. Report No.: ID 4037271. Available from : https://papers.ssrn.com/abstract=4037271
   Google Scholar
• Chua GT, Kwan MYW, Chui CSL, et al. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following comirnaty vaccination. Clin Infect Dis. 2022;75(4):673–681.
   PubMed Web of Science ®Google Scholar
• Farahmand R, Trottier CA, Kannam JP, et al. Incidence of myopericarditis and myocardial injury in Coronavirus disease 2019 vaccinated subjects. Am J Cardiol. 2022;164:123–130.
   PubMed Web of Science ®Google Scholar
• Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021;385:2140–2149.
   PubMed Web of Science ®Google Scholar
• Diaz GA, Parsons GT, Gering SK, et al. Myocarditis and pericarditis after vaccination for COVID-19. JAMA. 2021;326(12):1210–1212.
   PubMed Web of Science ®Google Scholar
• Li M, Yuan J, Lv G, et al. Myocarditis and Pericarditis following COVID-19 Vaccination: inequalities in Age and Vaccine Types. JPM. 2021;11:1106.
   Google Scholar
• Abraham N, Spruin S, Rossi T, et al. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: a Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines. Vaccine. 2022;40(32):4663–4671.
   PubMed Web of Science ®Google Scholar
• Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. 2022;327:331–340.
   PubMed Web of Science ®Google Scholar
• Su JR Myopericarditis following COVID-19 vaccination : updates from the Vaccine Adverse Event Reporting System (VAERS) [Internet]. 2021 cited 2022 Mar 22] Available from: https://stacks.cdc.gov/view/cdc/110920.
   Google Scholar
• Kim HW, Jenista ER, Wendell DC, et al. Patients with acute myocarditis following mRNA COVID-19 vaccination. JAMA Cardiol. 2021;6(10):1196–1201.
   PubMed Web of Science ®Google Scholar
• Massari M, Spila-Alegiani S, Morciano C, et al. Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study [Internet]. medRxiv 2022 Jul;22270020. [cited 2022 Mar 21]. Available from: https://www.medrxiv.org/content/10.1101/2022.02.07.22270020v1.
   Google Scholar
• Klein NP Rapid cycle analysis to monitor the safety of COVID-19 vaccines in near real-time within the Vaccine Safety Datalink : myocarditis and anaphylaxis [Internet]. 2021 cited 2022 Jul 26]. Available from 2022 Jul 26: https://stacks.cdc.gov/view/cdc/109493.
   Google Scholar
• Patone M, Mei XW, Handunnetthi L, et al. Risk of myocarditis following sequential COVID-19 vaccinations by age and sex. Circulation. 2021;146(10):743–754.
   Google Scholar
• Ab Rahman N, Lim MT, Lee FY, et al. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: a self-controlled case series study. Vaccine. 2022;40(32):4394–4402.
   PubMed Web of Science ®Google Scholar
• Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28(2):410–422.
   PubMed Web of Science ®Google Scholar
• Hause AM, Baggs J, Gee J, et al. Safety monitoring of an additional dose of COVID-19 Vaccine — United States, August 12–September 19, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(39):1379–1384.
   PubMed Web of Science ®Google Scholar
• Hause AM, Baggs J, Marquez P, et al. Safety monitoring of COVID-19 Vaccine booster doses among adults - United States, September 22, 2021 February 6, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:249–254.
   PubMed Web of Science ®Google Scholar
• Rosenblum HG, Gee J, Liu R, et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the vaccine adverse event reporting system and v-safe. Lancet Infect Dis. 2022;22(6):802–812.
   PubMed Web of Science ®Google Scholar
• Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. 2021;375:e068665.
   PubMedGoogle Scholar
• Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390–1399.
   PubMed Web of Science ®Google Scholar
• Niesen MJM, Pawlowski C, O’Horo JC, et al. Surveillance of safety of 3 doses of COVID-19 mRNA vaccination using electronic health records. JAMA Network Open. 2022;5(4):E227038.
   PubMed Web of Science ®Google Scholar
• Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021;385(23):2132–2139.
   PubMed Web of Science ®Google Scholar
• Bardenheier BH, Gravenstein S, Blackman C, et al. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. Vaccine. 2021;39(29):3844–3851.
   PubMed Web of Science ®Google Scholar
• Bardenheier BH, Gravenstein S, Blackman C, et al. Adverse events following one dose of mRNA COVID-19 vaccination among US nursing home residents with and without a previous SARS-CoV-2 infection. J Am Med Dir Assoc. 2021;22(11):2228–2232.
   PubMed Web of Science ®Google Scholar
• Jabagi MJ, Botton J, Bertrand M, et al. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older. JAMA. 2022;327(1):80–82.
   PubMed Web of Science ®Google Scholar
• Ling RR, Ramanathan K, Tan FL, et al. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis. Lancet Respir Med. 2022;10(7):679–688.
   PubMed Web of Science ®Google Scholar
• Chamling B, Vehof V, Drakos S, et al. Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol. 2021;110(11):1850–1854.
   PubMed Web of Science ®Google Scholar
• Heymans S, Cooper LT. Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms. Nat Rev Cardiol. 2022;19(2):75–77.
   PubMed Web of Science ®Google Scholar
• Li C, Chen Y, Zhao Y, et al. Intravenous injection of Coronavirus Disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in mouse model. Clin Infect Dis. 2022;74(11):1933–1950.
   PubMed Web of Science ®Google Scholar
• Chen M, Yuan Y, Zhou Y, et al. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Poverty. 2021;10(1):94.
   PubMed Web of Science ®Google Scholar
• Ling Y, Zhong J, Luo J. Safety and effectiveness of SARS-CoV-2 vaccines: a systematic review and meta-analysis. J Med Virol. 2021;93(12):6486–6495.
   PubMed Web of Science ®Google Scholar
• Pormohammad A, Zarei M, Ghorbani S, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel). 2021;9(5):467.
   PubMed Web of Science ®Google Scholar
• Sathian B, Asim M, Banerjee I, et al. Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: a systematic review and meta-analysis of vaccine clinical trials. Nepal J Epidemiol. 2021;11:959–982.
   PubMed Web of Science ®Google Scholar
• Yuan P, Ai P, Liu Y, et al. Safety, tolerability, and immunogenicity of COVID-19 vaccines: a systematic review and meta-analysis. medRxiv [Internet]. Available from: https://pubmed.ncbi.nlm.nih.gov/33173896/
   Google Scholar
• Wong H-L, Hu M, Zhou CK, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet. 2022;399(10342):2191–2199.
   PubMed Web of Science ®Google Scholar
• Truong DT, Dionne A, Muniz JC, et al. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after COVID-19 vaccination. Circulation. 2022;145(5):345–356.
   PubMed Web of Science ®Google Scholar
• Pillay J, Bialy L, Gaudet L, et al. Myocarditis and Pericarditis following COVID-19 Vaccination: rapid Systematic Review of Incidence, Risk Factors, and Clinical Course. medRxiv. Internet] 2021 Nov.19.21266605 [cited 2022 Mar 21].Available from https://www.medrxiv.org/content/10.1101/2021.11.19.21266605v1
   Google Scholar
• Fairweather D, Cooper LT, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. 2013;38(1):7–46.
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144(6):471–484.
   PubMed Web of Science ®Google Scholar
• Wereski R, Kimenai DM, Bularga A, et al. Risk factors for type 1 and type 2 myocardial infarction. Eur Heart J. 2022;43(2):127–135.
   PubMed Web of Science ®Google Scholar
• Singer ME, Taub IB, Kaelber DC. Risk of Myocarditis from COVID-19 Infection in People Under Age 20: a population-based analysis. medRxiv. 2021 Jul 7;23:21260998.
   Google Scholar